|
Jul 28
|
Biomark Diagnostics Full Year 2024 Earnings: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)
|
|
Dec 4
|
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
|
|
Nov 28
|
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
|
|
Nov 14
|
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
|
|
Aug 8
|
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
|